{
  "id": "3159708c-c241-6b23-e063-6394a90a01ff",
  "code": {
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
  },
  "name": "Ammonia N 13",
  "organization": "SOFIE Co. dba SOFIE",
  "effectiveTime": "20250327",
  "ingredients": [
    {
      "name": "SODIUM CHLORIDE",
      "code": "451W47IQ8X"
    },
    {
      "name": "AMMONIA N-13",
      "code": "9OQO0E343Z"
    }
  ],
  "indications": "1 INDICATIONS AND USAGE Ammonia N 13 Injection, USP is indicated for diagnostic Positron Emission Tomography ( PET ) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection, USP is a radioactive diagnostic agent for Positron Emission Tomography ( PET ) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease ( 1 ) .",
  "contraindications": "4 CONTRAINDICATIONS None. None ( 4 ) .",
  "warningsAndPrecautions": "5 WARNINGS AND PRECAUTIONS Ammonia N 13 Injection may increase the risk of cancer. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker ( 5.1 ) . 5.1 Radiation Risks Ammonia N 13 Injection may increase the risk of cancer. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [see Dosage and Administration ( . 2.4 ) ]",
  "adverseReactions": "6 ADVERSE REACTIONS No adverse reactions have been reported for Ammonia N 13 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems. However, the completeness of these sources is not known. No adverse reactions have been reported for Ammonia N 13 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting system ( 6 ) . To report SUSPECTED ADVERSE REACTIONS, contact SOFIE Co. at 800-207-1865 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
}